Stock Report

All about this stock under one free report Last Updated: 31-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

AstraZeneca - ADR Key Ratios

Stock Card factsheet share-fund-plan-icon

$162.70

up-down-arrow $-1.82 (-1.11%)

As on 28-Aug-2026 16:00EDT

Market cap

info icon

$252,329 Mln

Revenue (TTM)

info icon

$61,366 Mln

P/E Ratio

info icon

24.4

P/B Ratio

info icon

5.1

Div. Yield

info icon

2 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 0.63 6.41 8.61 11.32 15.75
EBIT -24.91 -9.31 22.42 23.90 20.52
Net Profit -18.61 2.20 25.95 19.21 22.59
EPS -18.55 2.26 25.89 19.20 18.49
Book Value -- -- 19.32 9.46 21.23
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 20.5714.6123.3424.0019.18
Net Margin info ----17.02----
Return on equity info 18.7213.0421.1122.9317.60
Return on Capital info 10.937.56--13.7410.15
Return on Assets info 7.435.147.139.406.86
Debt to Equity (x) info ----0.470.610.74

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
--
13.74
10.15
8.89
4.83
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

21.11

Higher than Peers by 36.04

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
21.11
22.93
17.60
15.63
8.62
Peer Median
-14.93
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

7.13

Higher than Peers by 10.62

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
7.13
9.40
6.86
6.03
3.26
Peer Median
-3.49
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

23.34

Higher than Peers by 22.40

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
23.34
24.00
19.18
18.53
8.64
Peer Median
0.94
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

17.02

Higher than Peers by 32.48

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
17.02
17.46
13.01
13.00
7.41
Peer Median
-15.46
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

8.61

Higher than Peers by 4.34

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
8.61
0.09
0.18
0.03
0.19
Peer Median
4.27
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

22.42

Higher than Peers by 74.50

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
22.42
35.89
22.21
121.56
278.93
Peer Median
-52.08
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

25.95

Higher than Peers by 4.92

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
25.95
45.77
18.14
81.11
2,835.71
Peer Median
21.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

25.89

Higher than Peers by 13.55

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
25.89
0.46
0.18
0.81
28.13
Peer Median
12.34
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

12.27

Higher than Peers by 14.42

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
12.27
--
--
--
--
Peer Median
-2.15
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.47

Lower than Peers by 0.33

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
0.47
0.61
0.74
0.73
0.79
Peer Median
0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.12

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
0.12
0.07
0.06
0.14
0.15
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.89

Lower than Peers by 0.40

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
0.89
0.94
0.93
0.82
0.86
Peer Median
1.29
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.67

Lower than Peers by 0.51

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
0.67
0.72
0.74
0.64
0.68
Peer Median
1.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

8.26

Higher than Peers by 7.96

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
8.26
8.32
6.17
5.34
2.88
Peer Median
0.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

26.02

Higher than Peers by 13.73

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
26.02
25.84
20.78
18.35
20.73
Peer Median
12.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.42

Higher than Peers by 0.11

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
0.42
0.54
0.53
0.46
0.44
Peer Median
0.31
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
--
82.12
66.34
70.16
71.34
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
--
203.44
191.66
223.60
201.65
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
--
496.71
123.58
128.49
79.20
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
--
-211.15
134.42
165.27
193.78
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

24.36

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
24.36
14.00
14.55
17.65
32.15
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

5.07

Higher than Peers by 4.48

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
5.07
2.95
2.51
2.69
2.85
Peer Median
0.59
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

1.96

Higher than Peers by 1.53

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
1.96
--
--
--
--
Peer Median
0.44
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

13.89

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
13.89
8.45
8.22
9.53
14.16
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

252,329

Higher than Peers by 251,863

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
AstraZeneca - ADR
252,329
--
--
--
--
Peer Median
466
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...